14 November 2026

publised in BioSpectrum Asia Edition

Asia makes the world’s antibiotics. So why do its patients wait longest for the new ones?

Asia carries the heaviest burden of drug-resistant infection on the planet and anchors the global antibiotic supply chain. Yet most new antibiotics reach its hospitals years late, or never. As resistance to last-resort drugs climbs, the region’s next battle against AMR is about economics and access as much as science. Here is what the data shows, who is breaking the pattern, and what would fix it.

Walk into the microbiology lab of almost any large tertiary hospital in Delhi, Dhaka, Jakarta or Manila, and you will hear a version of the same story. A patient in intensive care has a bloodstream infection. The culture comes back as carbapenem-resistant Klebsiella or Acinetobacter. The doctors know which newer drugs could work, because they read the same journals as their peers in Boston and London. The problem is that the drug is not registered in the country, or it is registered but not stocked, or it is stocked but priced beyond what the family can pay. So the team reaches for colistin, an old and toxic antibiotic, and hopes.